✦ LIBER ✦

Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN α-2a (40KD) (PEGASYS®)

✍ Scribed by Brian Bressler; Ka Wang; Joseph F. Grippo; E. Jenny Heathcote

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PEG-IFN alfa-2a (40kd) (Pegasys) plus am

✍ G. Ideo; A. Attili; G. Ruggiero; A. Craxi; G. Di Perri; A. Mangia; A. Picciotto; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 154 KB

1186 PEG-IFN alfa-2A (40KD) (PEGASYS) pl

✍ IDEO, G; ATTILI, A; BABUDIERI, S; CHIRIANNI, A; CRAXI, A; DIPERRI, G; FRANCAVILL 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB

Pharmacokinetics, pharmacodynamics and a

✍ Sulkowski, Mark S.; Rossio, Stephen J.; Arora, Sanjeev; Yalamanchili, Sreeni; La 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 525 KB

Pharmacokinetics of peginterferon ALFA-2

✍ R. Bruno; P. Sacchi; V. Ciappina; E. Maffezzini; S.F.A. Patruno; C. Zocchetti; G 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 319 KB

Efficacy, quality of life, safety, and t

✍ Kenneth D. Rothstein; Robert P. Perrillo; Joanne Imperial; Imtiaz Alam; Melissa 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 366 KB

743 The majority of patients with HBeAg-

✍ P. Marcellin; E. Bonino; G.K.K. Lau; P. Farci; C. Yurdaydin; T. Piratvisuth; R. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 115 KB